Phase II of sunitinib (Sutent) in first line for patients with locally advanced or metastatic papillary renal cell carcinoma - SUPAP.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SUPAP
- 19 Oct 2007 New trial record.